We use both our own and third-party cookies for statistical purposes and to improve our services. If you continue to browse, we consider that you accept the use of these.
 In Advanced Applications, Cofactor Genomics, Molecular Diagnostics, Q&A

Building Tools to Advance Precision Medicine for Cancer Patients

Raymund Bueno, PhD, Computational Biologist, at Cofactor Genomics share why he believes multidimensional biomarkers are a significant improvement over single analyte approaches. Watch the full video here or read the Q&A below.

Q: What’s your favorite part about working at Cofactor?

Raymund: My favorite part about work at Cofactor is being part of a team of fun and intelligent people. Being part of a company whose founders were part of the Genome project is inspiring as throughout my PhD training, I learned about how the technology from that project revolutionized biomedical research and see its impact on today’s world.

Q: What gets you most excited about the company’s future?

Raymund: I am most excited for the difference that our product will make in the field of cancer diagnostics and therapeutics. By focusing on multi-analyte biomarkers, we are moving closer to advancing precision medicine for cancer patients.

Q: How do you feel that your work impacts human health?

Raymund: We focus on multidimensional biomarkers which will potentially advance precision medicine for all cancer patients. A disease is very complex and involves various players and the accumulation of a number of changes, not just a single change. By taking a multi-dimensional approach we have a more involved understanding of this disease and how those changes are affecting the body.

Questions about Cofactor or our product offerings?  Reach out to schedule a time to speak with one of our Project Scientists today.

 

Recommended Posts

Leave a Comment

− 2 = 3

Start typing and press Enter to search